RAS mutations drive proliferative chronic myelomonocytic leukemia through the lysine methyltransferase 2A (KMT2A)–Polo-like kinase 1 (PLK1) axis [103]. This evidence concerns the gene KMT2A and chronic myelomonocytic leukemia.